These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 33163697)

  • 21. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer.
    Kestin LL; Martinez AA; Stromberg JS; Edmundson GK; Gustafson GS; Brabbins DS; Chen PY; Vicini FA
    J Clin Oncol; 2000 Aug; 18(15):2869-80. PubMed ID: 10920135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.
    Cetina L; Garcia-Arias A; Candelaria M; Cantú D; Rivera L; Coronel J; Bazan-Perkins B; Flores V; Gonzalez A; Dueñas-González A
    World J Surg Oncol; 2009 Feb; 7():19. PubMed ID: 19220882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term oncologic outcomes of localized high-risk prostate cancer undergoing brachytherapy combined with external-beam radiation therapy and maximal androgen blockade].
    Luo Y; Li MC; Qi HZ; Zhao JH; Han YL; Lin YH; Hou Z; Jiang YG
    Zhonghua Yi Xue Za Zhi; 2017 Jul; 97(26):2028-2032. PubMed ID: 28763873
    [No Abstract]   [Full Text] [Related]  

  • 24. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
    Brachman DG; Thomas T; Hilbe J; Beyer DC
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overuse of external beam radiotherapy for stage I endometrial cancer.
    Wright JD; Margolis B; Hou JY; Burke WM; Tergas AI; Huang Y; Hu JC; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2016 Jul; 215(1):75.e1-7. PubMed ID: 26875941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.
    Lee WR; Hall MC; McQuellon RP; Case LD; McCullough DL
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):614-23. PubMed ID: 11597800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
    Ishiyama H; Satoh T; Kitano M; Tabata K; Komori S; Ikeda M; Soda I; Kurosaka S; Sekiguchi A; Kimura M; Kawakami S; Iwamura M; Hayakawa K
    J Radiat Res; 2014 May; 55(3):509-17. PubMed ID: 24222312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative external beam irradiation with and without brachytherapy in pelvic node-positive IB1-IIA2 cervical cancer patients: a retrospective clinical study.
    Li L; Kou X; Feng X; Zhang M; Chao H; Wang L
    Radiat Oncol; 2015 Sep; 10():189. PubMed ID: 26377326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
    Rutenberg MS; Meister M; Amin PP; Hussain A; Naslund MJ; Kwok Y
    Brachytherapy; 2016; 15(6):722-729. PubMed ID: 27693225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs.
    Muka T; Li JJX; Farahani SJ; Ioannidis JPA
    Elife; 2023 Apr; 12():. PubMed ID: 37014058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of high dose rate interstitial boost brachytherapy after external beam radiation therapy in head and neck cancer--an Indian (single institutional) learning experience.
    Patra NB; Goswami J; Basu S; Chatterjee K; Sarkar SK
    Brachytherapy; 2009; 8(2):248-254. PubMed ID: 19230791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
    Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
    BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical results of external beam radiotherapy alone with a concomitant boost program or with conventional fractionation for cervical cancer patients who did not receive intracavitary brachytherapy.
    Matsuura K; Okabe T; Fujita K; Tanimoto H; Akagi Y; Kagemoto M
    J Radiat Res; 2012 Nov; 53(6):900-5. PubMed ID: 22859563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Template-based high-dose-rate interstitial brachytherapy in gynecologic cancers: a single institutional experience.
    Mahantshetty U; Shrivastava S; Kalyani N; Banerjee S; Engineer R; Chopra S
    Brachytherapy; 2014; 13(4):337-42. PubMed ID: 24176863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.